background: erythropoietin (epo) is a glycoprotein hormone function to regulate the production of red blood cells. deficiency of epo is known to cause anemia in chronically infected renal patients and they require regular blood transfusion. availability of recombinant epo has eliminated the need for blood transfusion and now it is extensively used for the treatment of anemia. glycosylation of e...

BACKGROUND AND PURPOSE Erythropoietin (EPO) has been demonstrated to possess significant neuroprotective effects in stroke. We determined if the nano-drug form of human recombinant EPO (PLGA-EPO nanoparticles [PLGA-EPO-NP]) can enhance neuroprotection at lower dosages versus human recombinant EPO (r-EPO). METHODS Established neonatal rat model of unilateral ischemic stroke was used to compare...

Objective: To compare cervical ripening in women having evening primrose oil with those not taking it. Study Design: Retrospective Cohort study. Setting: Department of Obs & Gynae, Abbasi Shaheed Hospital, Karachi. Period: July 2018 to April 2021. Material Method: Patients were divided into 2 groups, one (EPO) 1gm twice daily from 37 weeks till labor, given by her previous birth attendant. ...

Erythropoietin (EPO) plays an important role in erythropoiesis by its action blocking apoptosis of progenitor cells and protects both photoreceptors retinal ganglion from induced or inherited degeneration. A modified form EPO, EPO-R76E has attenuated erythropoietic activity but is effective inhibiting apoptosis, oxidative stress, inflammation several models In this study, we used recombinant Ad...

PURPOSE Expression of erythropoietin (Epo) and its receptor (Epo-R) has been shown in various normal and neoplastic nonhematopoietic tissues. This study, in non-small cell lung carcinoma, was designed to investigate the previously unreported expression of Epo and Epo-R as well as hypoxia-inducible factor-1alpha (HIF-1alpha), which is known to control Epo expression. EXPERIMENTAL DESIGN Sample...

traumatic brain injury (tbi) is one of the most common neurological diseases with no definite treatment. erythropoietin (epo) and progesterone (prog) have been shown to have neuroprotective effects in different types of experimental brain injury models. this study was designed to determine the effect of epo, prog and combination of epo/prog on neurological outcome after traumatic brain injury. ...

The main physiological regulator of erythropoiesis is the hematopoietic growth factor erythropoietin (EPO), which is induced in response to hypoxia. Binding of EPO to the EPO receptor (EPO-R), a member of the cytokine receptor superfamily, controls the terminal maturation of red blood cells. So far, EPO has been reported to act mainly on erythroid precursor cells. However, we have detected mRNA...

Cerebral hypoperfusion is associated with enhanced cognitive decline and increased risk of neuropsychiatric disorders. Erythropoietin (EPO) a neurotrophic factor known to improve function in preclinical clinical studies neurodegenerative psychiatric However, the application EPO limited due its erythropoietic activity that can adversely elevate hematocrit non-anemic populations. Carbamoylated er...

background: vhl (von hippel-lindau), runx-3 (runt-related transcription factor 3), e-cadherin (epithelial cadherin), p15 (ink4a, cyclin dependent kinase inhibitor), and p16 (ink4b) genes are essential in hematopoiesis. the aim of this study was to explore the correlation between gene expression and promoter methylation in cd34+ stem cells before and after differentiation to erythroid lineage. m...

Erythropoietin (EPO) is a factor essential for erythroid cell proliferation, differentiation, and survival. The production of EPO by the kidneys in response to hypoxia and anemia is well documented. To determine whether EPO is also produced by hematopoietic cells, we analyzed the expression of EPO in normal human hematopoietic progenitors and in their progeny. Undifferentiated CD34(+)lin- hemat...